The ability of angiotensin peptides to stimulate prostaglandin release and raise intracellular calcium levels by activating a phosphoinositide-specific phospholipase C was assessed in three human astrocytoma cell lines (CRTG3, STTG1, and VVITG2). The addition of angiotensin II to CRTG3 cells resulted in a dose-dependent release of prostaglandin E, and prostacyclin, the production of inositol 1,4,5-trisphosphate, and the mobilization of intracellular calcium. Angiotensin-(l-7), previously considered to be an inactive metabolite of angiotensin II, was as potent as angiotensin II for prostaglandin release but did not activate phospholipase C or mobilize intracellular calcium. In contrast, angiotensin-(2-8) caused only a slight increase in prostaglandin release, even though it was as effective as angiotensin II in augmenting inositol 1,4,5-trisphosphate production and calcium mobilization. Moreover, neither the release of prostaglandins in response to angiotensin II or angiotensin-(l-7) nor the mobilization of intracellular calcium in response to angiotensin II required extracellular calcium. Angiotensin II and angiotensin-(l-7) caused the release of prostaglandins from all three human astrocytoma cell lines, but changes in the level of intracellular calcium in response to angiotensin II only occurred in CRTG3 cells. Although previous studies have provided evidence for angiotensin receptor subtypes on the basis of selectivity of antagonists or signal transduction mechanisms, these data suggest that human astrocytes contain multiple angiotensin receptor subtypes on the basis of their response to different angiotensin heptapeptides -angiotensin-(1-7) and angiotensin-(2-8). Furthermore, the data also suggest that preferential production of angiotensin-(1-7) and angiotensin-(2-8) may be one level of regulation whereby a particular signal transduction pathway [i.e., calcium mobilization by angiotensin-(2-8) or prostaglandin release by angiotensin-(l-7)] is selectively activated. {Hypertension 1991;18:32-39)
I
t is well established that the central nervous system (CNS) 1 contains an intrinsic renin-angiotensin system (RAS) and that angiotensin II (Ang II) is involved in neural regulation of blood pressure; control of water intake and sodium appetite; and secretion of vasopressin, adrenocorticotropic hormone (ACTH), and other pituitary hormones. 1 Although it is accepted that Ang II is the biologically active peptide of the RAS, our recent evidence suggests that an N-terminaJ fragment of Ang II, angiotensin-(l-7) [Ang-(l-7)], possesses some of the ac-tions of Ang II. 2 " 4 In addition, the C-terminal heptapeptide angiotensin (2) (3) (4) (5) (6) (7) (8) [Ang- (2) (3) (4) (5) (6) (7) (8) or Ang III] is as potent as Ang II in producing central effects.
s - 6 However, neither of the heptapeptides possesses the entire complement of activities exhibited by Ang II. These findings thus suggest that endogenousry formed fragments of Ang II mediate the selective responses in cells of neural origin that account for the diverse actions of angiotensin in the CNS.
Although much of the early work on the brain RAS focused on neuronal elements, recent evidence suggests that astrocytes are a source for the synthesis of angiotensin precursors. Glial cells contain all of the components of the RAS 7 -8 and may be the primary neural source of angiotensinogen. 910 In addition, specific high affinity binding sites for Ang II have been identified in primary cultures of glial cells from the hypothalamus, brain stem, and spinal cord 1112 and in rat C6 glioma cells. 13 Functionally, Ang II stimulates the hydrolysis of phosphoinositides in primary cultures of rat glial cells 14 and causes the release of prostaglandin (PG) E? and prostacyclin (PGI 2 ) from human and rat astrocytes and rat C6 glioma cells. 15 " 18 In addition, Ang II depolarizes astrocytes in explant cultures of rat brain stem and spinal cord, an effect that is blocked by saralasin. 19 In an attempt to better understand the functional actions of endogenous angiotensin heptapeptides at the cellular level, we measured both the release of PGs and the changes in the intracellular concentration of Ca 2+ through activation of a phosphoinositide-specific phospholipase C in cultured human astrocytoma cells. The data suggest that astrocytes contain multiple angiotensin receptor subtypes, distinguishable by their responses to distinct angiotensin heptapeptides. Furthermore, our findings are the first to show that different pathways of signal transduction can be linked to the two angiotensin heptapeptides that are endogenously present in the brain. 
Materials

Cell Culture
Human astrocytoma cell lines (STTG1, CRTG3, and WITG2) were cultured from neoplastic brain tissues of patients undergoing excision of tumor masses and were histopathologically diagnosed as grade IV astrocytoma (glioblastoma multiforme). 20 Cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 4 mM L-glutamine, 100 units/ml penicillin G sodium, and 100 jig/ml streptomycin sulfate. Although morphologically heterogeneous, the majority of cells in all three lines were demonstrated to be positive for the astrocyte-specific intermediate filament component glial fibrillary acidic protein (GFAP) in cultures of early passage (60% of CRTG3, 80% of STTG1, and 20% of WITG2). 10 All three cultures were negative for the neuronal marker neuron-specific enolase. 10 Cultures showed a small amount of reactivity for fibronectin (CRTG1 5%, STTG1 6%, and WITG2 2%), using rabbit anti-human fibronectin (Cappel 1:5,000); however, GFAP and fibronectin have been reported to colocalize in human astrocytes in culture. 21 Astrocytes were grown at 37°C in a humidified atmosphere of 95% air and 5% CO 2 and were used between passage 5 and 30.
Determination of Prostaglandins
The release of PGE2 and PGI 2 (measured as the stable metabolite 6-keto-PGF lQ ) into the medium was determined using confluent cell monolayers in 24-well cluster plates. Cell monolayers were washed twice in Hanks' Balanced Salt Solution (HBSS) containing 5.5 mM glucose and 1.8 mM CaCl 2 and were subsequently incubated with angiotensin peptides for 15 minutes at 37°C in 5% CO2-95% air. Preliminary experiments showed that this time was optimal for the release of PG after stimulation with angiotensin peptides. At the end of the incubation, the medium was removed and stored at -20°C for subsequent measurements of PGE2 and 6-keto-PGF la by radioimmunoassay as described. 22 The cross-reactivity of each antibody was less than 0.5% for other PGs. 22 
Measurement of Inositol 1,4,5-Trisphosphate
IP 3 was measured by a radioreceptor assay, using canine cerebellar membranes purified according to the procedure for rat cerebellum 23 as a source of the IP 3 receptor. Human astrocytes resuspended at lxlO 7 cells/ml of HEPES-buffered Krebs' Ringer (125 mM NaCl, 5 mM KC1, 1.2 mM MgSO 4 , 6 mM glucose, 1 mM CaCl ? , and 25 mM HEPES, pH 7.5) containing 0.1% bovine serum albumin (BSA) were pretreated for 10 minutes with 10 mM LiCl 2 before treatment with various angiotensin peptides for 15 seconds at 37°C; in preliminary experiments, this time represented the peak production of EP 3 . The reaction was terminated by the addition of perchloric acid to 5% and neutralized by the addition of 6M KOH and 0.5 M Tris. After incubation on ice for 20 minutes and centrifugation for 10 minutes at 10,000g, the supernatant was assayed for IP 3 , essentially as described by Bredt et al. 23 Nonspecific binding was defined as binding not displaced by 1 /AM IP 3 .
Measurement of the Cytosolic Concentration of Calcium
Ca 2+ concentrations were measured using Fura-2 in astrocytes either growing as confluent monolayers on ALCAR coverslips or physically scraped from tissue culture flasks and measured in suspension at a concentration of 1 x 10* cell/ml. Cells in monolayer or suspension were equilibrated for 30 minutes at 37°C in HEPES-buffered Leibowitz 15 media (pH 7.4) containing 0.1% BSA and subsequently loaded with Fura-2 by incubation in 2 JAM Fura 2-AM in the same media for 30 minutes at 37°C. 24 The cells were then incubated for an additional 30 minutes in HEPES-buffered Krebs' Ringer containing 0.1% BSA, to completely hydrofyze the entrapped ester. The Fura-2 signal was calibrated using excitation wavelengths of 340 and 380 nm and an emission wavelength of 510 nm in an air turbine dual excitation spectrofluorometer. Maximal fluorescence of the Ca 2+ -saturated dye (F^,) was measured by the addition of 1 /AM ionomycin to cells on coverslips or after cells in suspension were lysed by the addition of 6 mg/ml digitonin. Minimal fluorescence was measured by the addition of 5 mM MnCl 2 to cells on coverslips or by the addition of Tris buffer (pH 8.5) to 32 mM and ethylene glycol bisO-aminoethyl etheryN,N,N',N'-tetraacetic acid (EGTA) to 5 mM to cells in suspension. The level of cytosolic Ca 2+ was calculated according to the procedure of Grynkiewicz et al. 25 Essentially identical results were obtained for cells in suspension or growing as monolayers on coverslips; therefore, cells in suspension were routinely used.
Statistics
The results are expressed as mean±SEM. The data for PG release were analyzed by paired Student's t tests corrected for multiple comparisons by the Bonferroni method. 26 A value of p<0.05 was considered significant. The increase in IP 3 levels is expressed as the percent of control, in the absence of any agonist, and of PG release, as percentage increase above basal, to control for variations in unstimulated PG levels in cells from different passages.
Results
Effect of Angiotensin Peptides on Prostaglandin Release
As shown in Figure 1 , Ang II (range, 0.1 nM to 10 /iM) significantly stimulated the release of PGs, producing a maximal response of 259±46% above basal levels (EG^IO nM) for PGEj and 185 ±80% above basal levels (ECso=50 nM) for 6-keto-PGF lco the stable metabolite of prostacyclin (n=6,p<0.05). Ang-(l-7) also produced a significant dose-dependent (0.1 nM to 10 /iM) increase in PG release that produced a maximal response of 265 ±37% above basal levels (ECso=l nM) for PGE2 (n=7, p<0.05) and 251 ±35% above basal levels (EQo=4O nM) for 6-keto-PGF la (n=7,p<0.05). In contrast, Ang-(2-8) did not alter basal release of PGE? or 6-keto-PGF la at a concentration of 10 nM; however, an increase in the dose of Ang-(2-8) between 10-fold and 1,000-fold produced a significant increase in the release of PGs. Ang I did not stimulate PG release at doses between 10 nM and 1 pM. Basal release of PGEj averaged 0.74+0.16 ng/mg protein while that of 6-keto-PGF la was 1.40±0.49 ng/mg protein. In two other human astrocytoma cell lines (STTG1 and WITG2), Ang II and Ang-(l-7) in doses of between 1 nM and 10 /iM also stimulated the release of both PGE2 and prostacyclin, with essentially the same order of potency (data not shown). Table 1 shows the effect of Ca 2+ on prostaglandin release in the CRTG3 astrocyte cell line. Removal of extracellular Ca 2+ by excess EGTA did not significantly inhibit the release of either PGE2 or 6-keto-PGF la by 100 nM Ang II or Ang-(l-7).
Effect of Angiotensin Peptides on Production of Inositol 1,4,5-Trisphosphate and Mobilization of Cytosolic Ca
2+
To determine whether angiotensin peptides activate a phosphoinositide-specific phospholipase C, intact as- 
Log DOSE (M) trocytes of the CRTG3 cell line were stimulated with angiotensin peptides and the level of IP 3 was measured after 15 seconds. Ang II (100 nM) caused a significant increase in the level of IP 3 to 145.5±4.6% of control (p=0.005), whereas 100 nM Ang-(2-8) tended to increase IP 3 to an average value of 123.7±9.1% of control levels (p=0.06), as shown in Table 2 . In contrast, Ang-(l-7) even at doses as high as 1 ^iM did not increase the level of EP 3 . Ang I (1 fiM) only produced a slight increase in IP 3 formation.
Because IP 3 is known to mobilize Ca 2+ from intracellular stores, we also measured changes in intracel- Intact CRTG3 cells were incubated with the indicated concentrations of angiotensin (Ang) peptides for 15 seconds at 37°C, and inositol 1,4,5-trisphosphate levels were measured using the radioreceptor assay as described in "Methods. •00 lular Ca 2+ levels in response to angiotensin peptides, in CRTG3 cells loaded with Fura-2. Ang II consistently produced an increase in the intracellular Ca 2+ concentration, averaging 190±18 nM above basal levels (n=7) in response to 100 nM Ang II ( Figure  2A) (Figure 3) . Mobilization of intracellular Ca 2+ by Ang II (100 nM) was essentially unchanged in both the presence and absence of 1 mM CaCl 2 ( Figures 3A  and 3B, respectively) . Moreover, the subsequent addition of Ca 2+ to cells maintained in Ca
-free medium and stimulated with 100 nM Ang II produced no further response ( Figure 3B ). Although 100 nM Ang II in the presence of 1 mM EGTA also mobilized intracellular Ca 2+ , the overall response was diminished (data not shown). Finally, preincubation with either verapamil (100 /xM, Figure 3C ) or nifedipine (1 fiM, Figure 3D ) had no effect on the subsequent Ca 2+ response to Ang II.
Compared with Ang II, Ang-(2-8) at a dose of 100 nM produced a similar increase in intracellular Ca 2+ (166±21 nM above basal levels, n=3) and blocked subsequent responses to Ang II, suggesting that activation occurred through the same angiotensin receptor subtype ( Figure 2B ). In contrast, Ang-(l-7), at concentrations of 100 nM and 1 uM, caused no increase in the intracellular Ca 2+ concentration and did not block a subsequent rise in Ca 2+ elicited by 100 nM Ang II [149±14 nM above basal (n=5) after Ang-(l-7) versus 190±18 nM alone ( Figure 2D) ]. Furthermore, addition of Ang-(l-7) to 10 fiM did not mobilize intracellular Ca
. Ang I, at a concentration of 100 nM, did not mobilize Ca
; however, at a concentration of 1 uM, Ang I produced a slight increase in the cytosolic concentration of Ca 2+ (56±1 nM above basal, n=3), suggesting that it binds only weakly to this subtype of angiotensin receptor. Further addition of Ang II (100 nM) produced a subsequent increase in the intracellular Ca 2+ concentration (120±4 nM above basal, n=3, Figure 2C ). The addition of a higher concentration of Ang I produced no further increase in intracellular Ca 2+ . In contrast to the finding in CRTG3 cells, neither Ang II nor the other angiotensin peptides caused an increase in the intracellular concentration of Ca 2+ in the human astrocytoma cell lines STTG1 and WITG2, even at 1 uM concentrations (data not shown). However, 100 nM bradykinin caused significant increases in cytosolic Ca 2+ in all three astrocytoma cell lines, indicating that each of these cell lines had the potential to release Ca 2+ in response to agonist stimulation.
Discussion
Ang II and Ang-(l-7) stimulated the release of both PGE2 and prostacyclin from three different human astrocytoma cell lines in culture. This finding expands our previous observation that Ang II enhances PGE2 and prostacyclin release from rat C6 cells, a clonal glial cell line. 1718 Moreover, the heptapeptide Ang-(l-7) was a potent stimulus for PG release from cultured human astrocytes, consistent with our previous finding that Ang-(l-7) causes PGE release from the vas deferens of rabbits 27 and rat C6 glioma cells. 18 The majority of cells in the astrocytoma cultures stain positively for the astrocyte marker GFAP and show little evidence of being neurons or fibroblasts; however, there is a remote possibility that our cultures may contain a small fraction of vascular cells. Regardless, analogous results in the C6 cell line, which is a clonal cell line of glial origin, strongly suggest that PGs are being produced by astrocytes in response to angiotensin peptides.
The finding that Ang-(l-7) causes release of PGs from human astrocytes complements other studies of the expression does not cause pressor or drinking responses, 30 it has been proposed that the heptapeptide acts as a subset of angiotensin receptors. In the rabbit vas deferens, Trachte et al 27 showed that, unlike Ang II and Ang-(2-8), Ang-(l-7) had no direct vasoconstrictor activity and did not alter release of norepinephrine even though it was a potent stimulus for PGE release. Our findings now reveal that Ang II causes PG synthesis and an increase in intracellular Ca 2+ through activation of a phosphoinositide-specific phospholipase C, whereas Ang-(l-7) has no effect on phospholipase C activation or Ca 2+ mobilization associated with its increase in PGs. Together, these findings strongly suggest the presence of multiple angiotensin receptor subtypes that respond to distinct angiotensin peptides.
Both Ang II and Ang-(2-8) activated a phosphoinositide-specific phospholipase C and increased the intracellular concentrations of Ca 2+ in the CRTG3 human astrocytoma cell line. Previous studies showed that Ang II activates a phosphoinositidespecific phospholipase C in vascular smooth muscle cells, 31 adrenal cortical cells, 32 hepatocytes, 33 neuronal cells, 34 - 35 and rat glial cells in culture.
14 This results in the hydrolysis of phosphatidylinositol 4,5-bisphosphate, the production of IP 3 and diacylglycerol, and the mobilization of cytosolic Ca 2+ from intracellular stores. Ca 2+ mobilization in CRTG3 cells in response to Ang II was not dependent on the presence of extracellular Ca
2+
; furthermore, the response was not eliminated in the presence of extracellular EGTA, although it was diminished, as has previously been reported for astrocytes in response to other Ca 2+ -mobilizing agonists. 36 Moreover, Ca 2+ mobilization was not inhibited by two different Ca 2+ channel blockers, indicating that the Ang II-induced Ca 2+ mobilization was from intracellular stores. These data indicate that Ang II-mediated increases in intracellular Ca 2+ in CRTG3 cells occur through activation of a phosphoinositide-specific phospholipase C, as reported previously for primary cultures of rat glial cells. -dependent phospholipase A2, freeing arachidonic acid from cellular phospholipids for PG metabolism. 37 Alternatively, diacylgrycerol produced from phosphoinositide hydrolysis may be deacylated by diacylglycerol lipase to produce free arachidonic acid. In contrast, Ang-(l-7) may activate a separate pathway in CRTG3 cells since stimulation of PG release occurred in the absence of a rise in intracellular Ca 2+ . Moreover, both Ang II and Ang-(l-7) stimulated the release of PGs from STTG1 and WITG2 cells although neither cell line mobilized intracellular Ca 2+ in response to application of angiotensin peptides. However, Ca 2+ elevations were induced in all three cell lines in the presence of bradykinin, indicating that both STTG1 and WITG2 cells had the potential to mobilize Ca 2+ in response to agonist stimulation. These findings suggest that STTG1 and WITG2 cells either lack the type of Ang II receptor that is coupled to activation of phospholipase C or that Ang II receptors in these cell lines are uncoupled from phospholipase C. Binding studies are necessary to distinguish these possibilities.
Enhancement of PG release in response to Ang II in STTG1 and WITG2 cells and to Ang-(l-7) in all three cell lines is independent of an increase in the cytosolic Ca 2+ concentration. Thus, neither activation of phospholipase C nor a direct opening of receptormediated or voltage-dependent Ca 2+ channels appears to be involved in the ability of Ang II to release PGs in STTG1 and WITG2 and Ang-(l-7) in all three cell lines. In FRTL5 thyroid cells, 38 MadinDarby canine kidney (MDCK) cells 39 and spinal cord neurons, 40 a,-adrenergic agonists stimulate both inositol phospholipid hydrolysis and arachidonic acid release. However, enhancement of PG metabolism is dependent on extracellular Ca 2+ and most likely occurs through a Ca 2+ -dependent activation of phospholipase A 2 . 37 In contrast, stimulation of PG release by bradykinin in MDCK cells, which also activates phospholipase C, does not depend on changes in intracellular Ca 2+ . 41 An alternative mechanism for a Ca 2+ -independent enhancement of PG release in response to angiotensin peptides is through activation of phosphatidylcholine-specific phospholipase C or phospholipase D, either of which could generate diacylglycerol as a source of arachidonic acid and both of which are active in the absence of Ca It may be argued that Ang-(l-7) in CRTG3 cells and both Ang II and Ang-(l-7) in STTG1 and WITG2 cells activate a receptor on a subset of astrocytes that causes an increase in intracellular Ca 2+ sufficient to activate phospholipase A 2 but undetectable by Fura-2 measurements in mixed populations of astrocytes. We believe, however, that this is not the case. Fura-2 measurements in CRTG3 cells detect fairly small Ca 2+ changes based on the magnitude of Ca 2+ mobilized in response to Ang II. In addition, the amounts of PGs produced by Ang II and Ang-(l-7) in the CRTG3 cells were similar. Moreover, this possibility does not contradict the suggestion that multiple angiotensin receptors exist since differences in Ca 2+ mobilization were not paralleled by changes in the magnitude of prostaglandin release.
The data obtained in the current experiments suggest that there are at least two angiotensin receptor subtypes-one acting through the activation of a phosphoinositide-specific phospholipase C and a second subtype that causes release of PGs independent of an increase in intracellular Ca 2+ . Although both subtypes are present on CRTG3 cells, only the Ca 2+ -independent type appears to be present on either STTG1 or WITG2 cell lines. Furthermore, the addition of Ang II to CRTG3 cells resulted in both an increase in the intracellular concentration of Ca phospholipase C and an enhancement of PG release. In contrast, Ang-(2-8) increased intracellular Ca 2+ and only minimally enhanced PG release (at higher peptide concentrations), and Ang-(l-7) increased PG release without affecting phospholipase C activity or Ca 2+ mobilization. Thus, the two angiotensin receptors differentially respond to angiotensin heptapeptides as well as activate distinct signal transduction pathways. This finding is not surprising since endothelin receptor subtypes in vascular smooth muscle cells are coupled to both phosphoinositide hydrolysis and arachidonic acid release in a parallel but independent manner. 44 In addition, gonadotropin-releasing hormone is independently coupled to both arachidonic acid release and inositol phosphate formation through different classes of receptors in cultured rat luteal cells. 45 Moreover, Ang II-induced production of PGE2 in kidney epithelial cells in culture can be dissociated from activation of a phosphoinositide-specific phospholipase C and the mobilization of intracellular Ca 2+ . 46 In addition, Ang-(1-7) as well as Ang II have recently been reported to activate phospholipase A 2 in kidney epithelial cells. 47 The ability of the heptapeptides to activate different signal transduction pathways suggests that extracellular processing of Ang I or Ang II to Ang-(2-8) or Ang-(l-7) by astrocytes (or other neural cells that are in close proximity to the astrocytes) would result in targeting of the angiotensin signal to a selective cellular response.
In more recent experiments, we have now clearly demonstrated that human astrocytes contain two distinct Ang II receptors, using newly developed subtype-selective Ang II receptor antagonists. 48 The subtype 1-selective antagonist DuP 753 inhibited the Ang II-induced PGE2 production and Ca 2+ mobilization. In contrast, CGP 42112A, the subtype 2-selective Ang II receptor antagonist, blocked the Ang II-induced production of PGI 2 , partially attenuated Ang II-induced PGEj production and inhibited PG production in response to Ang-(l-7). However, CGP 42112A was ineffective in inhibiting Ang II-induced Ca 2+ mobilization. These data provide further evidence that human astrocytes contain multiple angiotensin receptors.
In summary, using human astrocytes in culture, we showed that multiple angiotensin receptor subtypes exist, based on either their mechanisms of signal transduction or their selectivity for angiotensin heptapeptides. Activation of one type of angiotensin receptor by either Ang II or Ang- (2) (3) (4) (5) (6) (7) (8) causes an activation of a phosphoinositide-specific phospholipase C and an increase in the intracellular concentration of Ca 2+ . Further studies indicate that these responses are mediated by a subtype 1 receptor. 48 A second type of angiotensin receptor is coupled to the release of PGs and responds to both Ang II and the N-terminally directed heptapeptide Ang-(l-7). We have subsequently identified this receptor as the subtype 2 receptor. 48 Moreover, enhancement of PG release in response to Ang-(1-7) in all three cell lines and to Ang II in at least two of the three cell lines is not dependent on an increase in the cytosolic Ca 2+ concentration, suggesting that PG release is mediated by a Ca 2+ -independent phospholipase activity. In addition, the release of PGs from astrocytes in response to Ang-(l-7) further substantiates the role of this heptapeptide in brain function and may represent its mode of action within the CNS. That this heptapeptide does not uniformly act in a manner identical to Ang II provides a further explanation for the fact that its biological actions were overlooked previously.
